Optimal dose of etanercept in the treatment of rheumatoid arthritis

Elizabeth Mary Curtis, Jonathan Lewis MarksDepartment of Rheumatology, University Hospital Southampton, Southampton, Hampshire, UKAbstract: Etanercept (ETN) is one of a number of biological therapies targeting the proinflammatory cytokine tumor necrosis factor-alpha that have demonstrated efficacy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Curtis EM, Marks JL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/d11f11d8cc3d4f50ad7576ab43040d03
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d11f11d8cc3d4f50ad7576ab43040d03
record_format	dspace
spelling	oai:doaj.org-article:d11f11d8cc3d4f50ad7576ab43040d032021-12-02T02:41:10ZOptimal dose of etanercept in the treatment of rheumatoid arthritis1179-156Xhttps://doaj.org/article/d11f11d8cc3d4f50ad7576ab43040d032014-03-01T00:00:00Zhttp://www.dovepress.com/optimal-dose-of-etanercept-in-the-treatment-of-rheumatoid-arthritis-a16197https://doaj.org/toc/1179-156X Elizabeth Mary Curtis, Jonathan Lewis MarksDepartment of Rheumatology, University Hospital Southampton, Southampton, Hampshire, UKAbstract: Etanercept (ETN) is one of a number of biological therapies targeting the proinflammatory cytokine tumor necrosis factor-alpha that have demonstrated efficacy in the management of rheumatoid arthritis (RA). As experience has grown, a number of different treatment strategies have been investigated to ascertain the optimal conditions for use of ETN in RA and maximize the clinical gains from therapy. These have included the use of higher- and lower-dose treatment regimens, ETN as a monotherapy or in combination with other nonbiologic disease-modifying antirheumatic drugs, the use of ETN in very early clinical disease, and intraarticular ETN administration for resistant synovitis. Recent trials have focused on phased dose reduction or withdrawal of ETN in patients achieving low disease activity states or clinical remission. This review summarizes existing data regarding the optimal timing of ETN initiation and dosing regimens and also evaluates more recent evidence regarding dose-reduction strategies that offer the possibility of biologic-free remission in RA.Keywords: rheumatoid arthritis, etanercept, biologics, antirheumatic agents, monoclonal antibodies, anti-TNFCurtis EMMarks JLDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2014, Iss default, Pp 27-38 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Curtis EM Marks JL Optimal dose of etanercept in the treatment of rheumatoid arthritis
description	Elizabeth Mary Curtis, Jonathan Lewis MarksDepartment of Rheumatology, University Hospital Southampton, Southampton, Hampshire, UKAbstract: Etanercept (ETN) is one of a number of biological therapies targeting the proinflammatory cytokine tumor necrosis factor-alpha that have demonstrated efficacy in the management of rheumatoid arthritis (RA). As experience has grown, a number of different treatment strategies have been investigated to ascertain the optimal conditions for use of ETN in RA and maximize the clinical gains from therapy. These have included the use of higher- and lower-dose treatment regimens, ETN as a monotherapy or in combination with other nonbiologic disease-modifying antirheumatic drugs, the use of ETN in very early clinical disease, and intraarticular ETN administration for resistant synovitis. Recent trials have focused on phased dose reduction or withdrawal of ETN in patients achieving low disease activity states or clinical remission. This review summarizes existing data regarding the optimal timing of ETN initiation and dosing regimens and also evaluates more recent evidence regarding dose-reduction strategies that offer the possibility of biologic-free remission in RA.Keywords: rheumatoid arthritis, etanercept, biologics, antirheumatic agents, monoclonal antibodies, anti-TNF
format	article
author	Curtis EM Marks JL
author_facet	Curtis EM Marks JL
author_sort	Curtis EM
title	Optimal dose of etanercept in the treatment of rheumatoid arthritis
title_short	Optimal dose of etanercept in the treatment of rheumatoid arthritis
title_full	Optimal dose of etanercept in the treatment of rheumatoid arthritis
title_fullStr	Optimal dose of etanercept in the treatment of rheumatoid arthritis
title_full_unstemmed	Optimal dose of etanercept in the treatment of rheumatoid arthritis
title_sort	optimal dose of etanercept in the treatment of rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/d11f11d8cc3d4f50ad7576ab43040d03
work_keys_str_mv	AT curtisem optimaldoseofetanerceptinthetreatmentofrheumatoidarthritis AT marksjl optimaldoseofetanerceptinthetreatmentofrheumatoidarthritis
_version_	1718402316658278400

Optimal dose of etanercept in the treatment of rheumatoid arthritis

Ejemplares similares